Predictive and Presymptomatic Testing Market Size (2024 - 2029)

Predictive and Presymptomatic Testing Market Analysis

The predictive and presymptomatic testing market is poised to grow at a CAGR of 8.4% over the forecast period.

The emergence of COVID-19 had its impact on the predictive and presymptomatic testing market as during the initial pandemic days there were strict lockdown restrictions imposed by the governments to curb the spread of COVID-19 which led to a decline in the number of predictive and presymptomatic testing. However, the market is recovering since the lockdown restrictions were lifted around the world and as the cases of COVID-19 are on the decline and the demand for predictive and presymptomatic tests is increasing. Hence, the studied market is expected to grow over the forecast period.

The market for predictive and presymptomatic testing is expected to grow over the forecast period due to factors such as the increasing prevalence of genetic disorders and rising demand for genetic counseling as they can be used to determine whether the patient has a hereditary disease-causing mutation or genetic disorders. Also, the rising awareness regarding genetic diseases among the global population is leading to an increase in demand for genetic counseling, thereby contributing to the growth of the market. For instance, the NHP data published in June 2021 stated that 300 million people are living with a rare disease worldwide and 70% that genetic rare diseases start in childhood. Similarly, according to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people. Also, as per the PHO statistics in 2021, about 10,000 diseases are monogenetic worldwide. Such a high prevalence of rare hereditary diseases and genetic disorders is expected to contribute to the demand for predictive and presymptomatic testing, thereby boosting the market growth.

Furthermore, the launch of new predictive and presymptomatic testing services across the globe, increasing investments, rising research and development activities, and adoption of key strategic initiatives by key market players are expected to contribute to the significant growth of the market. For instance, in September 2021, MedGenomeLabs launched its direct-to-consumer website, Genessense for consumers in India. The company offered two tests, Kardiogen and Curegen, through the Genessense website e-commerce platforms. Kardiogenis a polygenic risk score-based predictive test for coronary artery disease with a proven specificity of 90% for the Indian population. Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period. However, the high costs of tests and ethical issues in predictive testing are expected to restrain the development of the market.

Predictive and Presymptomatic Testing Industry Segmentation

As per the scope of the report, the predictive and presymptomatic test is a type of genetic test, which is used for the detection of gene mutations for disorders that appear in later stages of life. Predictive and presymptomatic testing finds immense potential among people, who have a family member with a genetic disorder. This test is particularly effective when no features of the disorder are visible at the time of testing. The Predictive and Presymptomatic Testing market is Segmented by Condition (Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer's Disease, Multiple Endocrine Neoplasia Type - 2, and Haemochromatosis), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.